- Open
- 0.17
- High
- 0.16
- Low
- 0.16
- Close
- 0.16
- Change
- -0.01 (-3.03%)
- Volume
- 82,474
| 18 Nov 2026 | 07:33:54 | Ethics submission for Ox-1 Phase 1 study |
| 16 Nov 2026 | 07:00:08 | Investor Conference Attendance |
| 22 Oct 2026 | 14:44:32 | Result of Annual General Meeting |
| 19 Oct 2026 | 07:00:07 | Ox-1 Preclinical Data Package Complete |
| 14 Oct 2026 | Annual Report and Accounts (to 2026-03-31) | |
| 29 Aug 2025 | Annual Report and Accounts (to 2025-03-31) | |
| 15 Jul 2024 | Annual Report and Accounts (to 2024-03-31) |
TheraCryf PLC develops therapeutics for brain disorders, focusing on neuropsychiatry, particularly addiction and fatigue. Its lead program is an orexin-1 antagonist targeting binge eating disorder, while a second program involves a dopamine transporter antagonist aimed at fatigue related to conditions like multiple sclerosis. The company also collaborates with Erasmus Medical Centre on a grant-funded project for SFX-01, a treatment for glioblastoma. TheraCryf operates as a virtual biotech, outsourcing research and development while aiming to license its drug candidates to larger pharmaceutical companies after reaching proof-of-concept trials.
| 18 Nov 2026 | 07:33:54 | Ethics submission for Ox-1 Phase 1 study |
| 16 Nov 2026 | 07:00:08 | Investor Conference Attendance |
| 22 Oct 2026 | 14:44:32 | Result of Annual General Meeting |
| 19 Oct 2026 | 07:00:07 | Ox-1 Preclinical Data Package Complete |
| 14 Oct 2026 | Annual Report and Accounts (to 2026-03-31) | |
| 29 Aug 2025 | Annual Report and Accounts (to 2025-03-31) | |
| 15 Jul 2024 | Annual Report and Accounts (to 2024-03-31) |
TheraCryf PLC develops therapeutics for brain disorders, focusing on neuropsychiatry, particularly addiction and fatigue. Its lead program is an orexin-1 antagonist targeting binge eating disorder, while a second program involves a dopamine transporter antagonist aimed at fatigue related to conditions like multiple sclerosis. The company also collaborates with Erasmus Medical Centre on a grant-funded project for SFX-01, a treatment for glioblastoma. TheraCryf operates as a virtual biotech, outsourcing research and development while aiming to license its drug candidates to larger pharmaceutical companies after reaching proof-of-concept trials.
| 13 Oct 2026 | 10:56:40 | Holding(s) in Company |
| 25 Sept 2026 |
| Week Ahead: Greggs, Saga, Topps Tiles, Wetherspoons |
| 14 May 2026 | AIM movers: TheraCryf progresses towards Ox-1 phase 1 trial and ex-dividends |
| 14 Apr 2026 | AIM movers: James Cropper profit recovery and TheraCryf turns down approach for main asset |
| 13 Oct 2026 | 10:56:40 | Holding(s) in Company |
| 25 Sept 2026 |
| Week Ahead: Greggs, Saga, Topps Tiles, Wetherspoons |
| 14 May 2026 | AIM movers: TheraCryf progresses towards Ox-1 phase 1 trial and ex-dividends |
| 14 Apr 2026 | AIM movers: James Cropper profit recovery and TheraCryf turns down approach for main asset |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £294m | -0.2% | |
| £98m | -0.2% | |
| £6m | -0.7% | |
| £5m | -0.7% | |
TCFTheracryf PLC | £4m | -0.2% |
| £4m | -0.3% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £294m | -0.2% | |
| £98m | -0.2% | |
| £6m | -0.7% | |
| £5m | -0.7% | |
TCFTheracryf PLC | £4m | -0.2% |
| £4m | -0.3% |